Myeloperoxidase Inhibition Ameliorates Plaque Psoriasis in Mice
Savannah D Neu1,2, Anna Strzepa1,3, Dustin Martin4
1Versiti Blood Research Institute, Milwaukee, WI 53201, USA.
Abstract:
Plaque psoriasis is a common inflammatory condition of the skin characterized by red, flaking lesions. Current therapies for plaque psoriasis target many facets of the autoimmune response, but there is an incomplete understanding of how oxidative damage produced by enzymes such as myeloperoxidase contributes to skin pathology. In this study, we used the Aldara (Imiquimod) cream model of plaque psoriasis in mice to assess myeloperoxidase inhibition for treating psoriatic skin lesions. To assess skin inflammation severity, an innovative mouse psoriasis scoring system was developed. We found that myeloperoxidase inhibition ameliorated psoriasis severity when administered either systemically or topically. The findings of this study support the role of oxidative damage in plaque psoriasis pathology and present potential new therapeutic avenues for further exploration.
Insights
Myeloperoxidase inhibition effectively treats plaque psoriasis symptoms in a mouse model. This study highlights oxidative damage
Area of Science:
- Dermatology
- Immunology
- Oxidative Stress
Background:
- Plaque psoriasis is a chronic inflammatory skin disease.
- Current treatments address autoimmune responses but not fully oxidative damage.
- The role of myeloperoxidase (MPO) in psoriasis pathology is not well understood.
Purpose of the Study:
- To investigate the therapeutic potential of myeloperoxidase inhibition in a mouse model of plaque psoriasis.
- To evaluate the efficacy of systemic and topical MPO inhibition on psoriatic skin lesions.
- To develop a novel scoring system for assessing skin inflammation severity in mice.
Main Methods:
- Utilized the Aldara (Imiquimod) cream-induced mouse model of plaque psoriasis.
- Administered myeloperoxidase inhibitors systemically and topically.
- Developed and employed an innovative mouse psoriasis scoring system to quantify inflammation severity.
Main Results:
- Myeloperoxidase inhibition significantly ameliorated psoriasis severity in the mouse model.
- Both systemic and topical administration of MPO inhibitors demonstrated therapeutic effects.
- The developed scoring system provided a reliable measure of skin inflammation.
Conclusions:
- Oxidative damage mediated by myeloperoxidase plays a significant role in plaque psoriasis pathology.
- Inhibiting myeloperoxidase presents a promising therapeutic strategy for plaque psoriasis.
- Further research into MPO-targeted therapies for psoriasis is warranted.
